Evidence map›Paper›PMID 34943637›Full record

ArticleDiagnostics (Basel, Switzerland)2021

A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3).

Alice Laffi, Marzia Colandrea, Giuseppe Buonsanti, Samuele Frassoni, Vincenzo Bagnardi, Francesca Spada, Eleonora Pisa, Massimo Barberis, Manila Rubino, Chiara Maria Grana and 2 more

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Alice LaffiDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.ORCID 0000-0001-7458-3366
Marzia ColandreaDivision of Nuclear Medicine, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Giuseppe BuonsantiDivision of Nuclear Medicine, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Samuele FrassoniDepartment of Statistics and Quantitative Methods, University of Milano-Bicocca, 20126 Milan, Italy.
Vincenzo BagnardiDepartment of Statistics and Quantitative Methods, University of Milano-Bicocca, 20126 Milan, Italy.
Francesca SpadaDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.ORCID 0000-0003-3642-0798
Eleonora PisaDivision of Pathology and Laboratory Medicine, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Massimo BarberisDivision of Pathology and Laboratory Medicine, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.ORCID 0000-0002-0943-4804
Manila RubinoDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Chiara Maria GranaUnit of Radiometabolic Therapy, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Francesco CeciDivision of Nuclear Medicine, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Nicola FazioDivision of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy.ORCID 0000-0001-6869-0704
Ripamonti · ITEuropean Institute of Oncology · ITUniversity of Milano-Bicocca · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Grade 3 (G3) neuroendocrine tumors (NETs) are a novel category among digestive neuroendocrine neoplasms, characterized by Ki-67 >20% and a well-differentiated morphology, presenting high intra-tumor heterogeneity. We aimed to explore the role of dual-tracer PET imaging (

Indexed as

18F-FDG68GaNET G3neuroendocrinePET/CT

Identifiers

PMID34943637
PMCPMC8700454
OpenAlexW4200026934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.